MetaCap

Alterity Therapeutics (ATHE) vs Nasus Pharma (NSRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed Nasus Pharma (NSRX) over the past year, losing 56.7% versus a loss of 68.4%. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%NSRX-68.41%
+75%-2%-79%
Nov 21, 20251 yearNov 20, 2026
ATHE-71.05%NSRX-71.73%
+7%-35%-77%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus NSRX key metrics
MetricATHENSRX
Share price$1.52$2.29
Market cap$29.02M$26.82M
1-day change-8.16%-10.20%
YTD return-50.65%-74.97%
1-year return-56.70%-68.41%
5-year return-85.38%—
EPS (TTM)$-0.90$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.24B
Net income (latest FY)—$-5.86M
Operating margin—-0.40%
Net margin—-0.47%
52-week high$5.89$9.50
52-week low$1.52$1.98
Distance from 52-week high-74.19%-75.89%
Analyst consensusnonebuy
Avg. price target upside+771.71%+758.95%
Average volume89.63K16.80K
Shares outstanding19.09M11.71M
Employees117
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATHE has outperformed NSRX by 11.7 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ATHE vs NSRX FAQ

Which is bigger, Alterity Therapeutics or Nasus Pharma?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, ATHE or NSRX?

ATHE returned -56.70% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Nasus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons